Chicago-based CRISPR technology company Syntax Bio says it has developed tech which automates the slow, manual process of ...

Gain insights into the U.S. market, valued at $5.9 Billion in 2024, and China, forecasted to grow at an impressive 14.4% CAGR to reach $7.8 Billion by 2030. Discover growth trends in other key regions ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...

In a groundbreaking fusion of artificial intelligence and gene editing, researchers are leveraging machine learning to enhance CRISPR technology’s precision and efficiency. This integration is opening ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

You've probably heard about the gene-editing technology CRISPR. The massive biotech breakthrough, which has emerged in the last decade, has mainly been touted for the ways it will let scientists edit ...

One of the most well-known versions of the gene-editing tool CRISPR may not work in a large proportion of the population, according to recent research out of Stanford University in California. CRISPR, ...

Researchers used CRISPR to change the number of chromosomes in Arabidopsis by fusing chromosome arms, reducing the genome from ten to eight chromosomes. The plants grew normally but showed reduced ...

Key opportunities in the market include leveraging CRISPR's precision for improved crop traits, meeting food security demands amid climate change, and sustainable agriculture trendsDublin, Dec. 09, ...